Voronoi is a pioneering brand that specializes in the development of Kinase Inhibitors, a targeted therapy for various diseases. With a team of highly skilled and experienced professionals, Voronoi is at the forefront of pharmaceutical innovation, boasting a workforce of around 120 experts dedicated to drug development. They possess a state-of-the-art R&D facility, including an AI research center, animal testing center, and synthesis research center.

What sets Voronoi apart is their extensive Kinase Full Profiling Database, which houses an impressive 550,000 experimental compound data, making it the largest of its kind in the country. By leveraging their proprietary AI platform, VORONOMICS®, Voronoi has successfully shortened the average drug development period from 4-4. 5 years to just 1-1.

5 years. This breakthrough technology aids in molecular modeling, structural biology collaboration, and various stages of drug development. Since its establishment in 2015, Voronoi has been recognized for its significant contributions to the field.

They have received prestigious awards, secured partnerships with renowned institutions like Harvard DFCI, and achieved remarkable milestones, including FDA approvals and technology exports to global markets. With their commitment to excellence, Voronoi continues to revolutionize the pharmaceutical industry and improve the lives of countless patients worldwide